(Z)-4-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (Z)-4-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)benzoic acid
• 英文别名: 4-[(4-oxo-2-thioxothiazolidin-5-ylidene)methyl]benzoic acid；4-[(Z)-(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]benzoic acid；4-[(Z)-(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]benzoic acid
• 化学式: C₁₁H₇NO₃S₂
• mdl: MFCD04969080
• 分子量: 265.313
• InChiKey: CEGWYNRNQDQLNJ-YVMONPNESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  124
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (Z)-4-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)benzoic acid 在 氯化亚砜 作用下， 以 1,4-二氧六环 为溶剂， 生成 4-[(Z)-(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]benzoyl chloride
  参考文献：
  名称：

  EP1354880

  摘要：

  公开号：
• 作为产物：
  描述：

  methyl 4-[(Z)-(4-oxo-2-sulfanyl-1,3-thiazol-5(4H)-ylidene)methyl]benzoate 在 盐酸 、 水 、 溶剂黄146 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.0h， 生成 (Z)-4-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)benzoic acid
  参考文献：
  名称：

  EP1354880

  摘要：

  公开号：

文献信息

• [EN] INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME<br/>[FR] INHIBITEURS DU COMPLEXE D'ACTIVATION DE TRANSCRIPTION DU RÉCEPTEUR NOTCH ET PROCÉDÉS D'UTILISATION DE CES DERNIERS
  申请人：UNIV MIAMI

  公开号：WO2016154255A1

  公开（公告）日：2016-09-29

  Disclosed herein are inhibitors of the Notch transcriptional activation complex, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein can include compounds of Formula (I) and pharmaceutically acceptable salts thereof: Formula (I), wherein the substituents are as described.

  本文披露了Notch转录激活复合物的抑制剂，以及它们在治疗或预防疾病（如癌症）中的使用方法。本文描述的抑制剂可以包括式（I）的化合物及其药用可接受盐：式（I），其中取代基如所述。
• Inhibitors of the Notch transcriptional activation complex and methods for use of the same
  申请人：UNIVERSITY OF MIAMI

  公开号：US10501413B2

  公开（公告）日：2019-12-10

  Disclosed herein are inhibitors of the Notch transcriptional activation complex, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein can include compounds of Formula (I) and pharmaceutically acceptable salts thereof: Formula (I), wherein the substituents are as described.

  本文公开了 Notch 转录激活复合物的抑制剂，以及将其用于治疗或预防癌症等疾病的方法。本文所述的抑制剂可包括式（I）化合物及其药学上可接受的盐类：式 (I)，其中取代基如所述。
• Thiazolidinone–Peptide Hybrids as Dengue Virus Protease Inhibitors with Antiviral Activity in Cell Culture
  作者：Christoph Nitsche、Verena N. Schreier、Mira A. M. Behnam、Anil Kumar、Ralf Bartenschlager、Christian D. Klein

  DOI：10.1021/jm400828u

  日期：2013.11.14

  The protease of dengue virus is a promising target for antiviral drug discovery. We here report a new generation of peptide hybrid inhibitors of dengue protease that incorporate N-substituted 5-arylidenethiazolidinone heterocycles (rhodanines and thiazolidinediones) as N-terminal capping groups of the peptide moiety. The compounds were extensively characterized with respect to inhibition of various proteases, inhibition mechanisms, membrane permeability, antiviral activity, and cytotoxicity in cell culture. A sulfur/oxygen exchange in position 2 of the capping heterocycle (thiazolidinedione-capped vs rhodanine-capped peptide hybrids) has a significant effect on these properties and activities. The most promising in vitro affinities were observed for thiazolidinedione-based peptide hybrids containing hydrophobic groups with K-i values between 1.5 and 1.8 mu M and competitive inhibition mechanisms. Rhodanine-capped peptide hybrids with hydrophobic substituents have, in correlation with their membrane permeability, a more pronounced antiviral activity in cell culture than the thiazolidinediones.
• Pyrrolidine Inhibitors of Human Cytosolic Phospholipase A₂
  作者：Kaoru Seno、Takayuki Okuno、Koichi Nishi、Yasushi Murakami、Fumihiko Watanabe、Takaharu Matsuura、Masaaki Wada、Yasuhiko Fujii、Masaaki Yamada、Tomoyuki Ogawa、Tetsuo Okada、Hiroshi Hashizume、Makoto Kii、Shin-ichiro Hara、Sanji Hagishita、Shozo Nakamoto、Katsutoshi Yamada、Yukiko Chikazawa、Masahiko Ueno、Isao Teshirogi、Takashi Ono、Mitsuaki Ohtani

  DOI：10.1021/jm9905155

  日期：2000.3.1
• New cholesterol esterase inhibitors based on rhodanine and thiazolidinedione scaffolds
  作者：Sabrina Heng、William Tieu、Stephanie Hautmann、Kevin Kuan、Daniel Sejer Pedersen、Markus Pietsch、Michael Gütschow、Andrew D. Abell

  DOI：10.1016/j.bmc.2011.10.042

  日期：2011.12

  We present a new class of inhibitors of pancreatic cholesterol esterase (CEase) based on 'priviledged' 5-benzylidenerhodanine and 5-benzylidene-2,4-thiazolidinedione structural scaffolds. The lead structures (5-benzylidenerhodanine 4a and 5-benzylidene-2,4-thiazolidinedione 4b) were identified in an in-house screening and these inhibited CEase with some selectivity over another serine hydrolase, acetylcholinesterase (AChE) (4a, CEase IC50 = 1.76 mu M vs AChE IC50 = 5.14 mu M and 4b, CEase IC50 = 5.89 mu M vs AChE IC50 > 100 mu M). A small library of analogs (5a-10a) containing a core amino acid in place of the glycerol group of the lead structures, was prepared to explore other potential binding interaction with CEase. These analogs inhibited CEase with IC50 values ranging from 1.44 to 85 mu M, with the majority exhibiting some selectivity for CEase versus AChE. The most potent compound of the library (10a) had 17-fold selectivity over AChE. We also report molecular docking (with CEase) and detailed kinetic analysis on the amino acid analogs to further understand the associated structure-activity relationships. (C) 2011 Elsevier Ltd. All rights reserved.